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Podoplanin is a small mucin-like transmembrane protein, widely expressed in various specialised cell types throughout the body.
Here, we revisit the mechanism of podoplanin-mediated tumour invasion. We compare molecular pathways leading to single and
collective cell invasion and discuss novel distinct concepts of tumour cell invasion.
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Invasion of cells into the surrounding tissue and destruction of
normal tissue architecture are two hallmarks of malignant
tumours. Morphologically, two patterns of tumour invasion can
be distinguished: single cell and collective cell invasion. Investiga-
tions aimed at unravelling the molecular mechanisms underlying
tumour cell invasion have identified various pathways that
determine the invasive potential and the invasion pattern of
tumour cells (Friedl and Wolf, 2003). The invasion of single cells
and small groups of cells is often correlated with dramatic changes
in the expression and function of adhesive (e.g. cadherins,
immunoglobulin domain-containing cell adhesion molecules)
and regulatory proteins (e.g. Snail family members, transforming
growth factor b). These changes are reminiscent of early
developmental processes, in particular during neurulation and
gastrulation, when cells acquire a migratory, mesenchymal
phenotype. During this so-called epithelial–mesenchymal transi-
tion (EMT) cells lose epithelial markers, such as E-cadherin, and
gain the expression of mesenchymal markers, such as N-cadherin
and vimentin. The exact role of EMT in tumour progression is
still under debate, yet EMT is thought to be particularly important
in cancers with single cell migration and early dissemination
of tumour cells (Thiery, 2002; Lee et al, 2006). In contrast, the
invasion of large cell sheets into neighbouring tissue, often called
collective cell migration, is less well understood. These cell sheets
maintain the expression of epithelial adhesion structures but can
nonetheless invade into the surrounding tissue and thereby
destroy the host organ.
Recent experimental results have demonstrated that podoplanin,
a small mucin-like protein, mediates a pathway leading to
collective cell migration and invasion in vivo and in vitro (Wicki
et al, 2006). In this review, we will focus on the molecular basis
underlying the phenomenon of cell invasion induced by podopla-
nin, and discuss potential implications for cancer diagnosis and
treatment.
PODOPLANIN IS EXPRESSED IN MOST HUMAN
TISSUES
Human podoplanin (T1a-2, aggrus and gp36) is a 38kDa type-1
transmembrane glycoprotein consisting of 162 amino acids, nine
of which form the intracellular domain. The extracellular domain
is highly O-glycosylated, with sialic acid, a-2,3 linked to galactose,
forming the main part of the protein’s carbohydrate moieties.
In normal human tissue, podoplanin is expressed in kidney
podocytes (Breiteneder-Geleff et al, 1999), in skeletal muscle,
placenta, lung and heart (Martin-Villar et al, 2005), in myofibro-
blasts of the breast and salivary glands, in osteoblasts and
mesothelial cells (Ordonez, 2006b). It is also expressed on the
apical surface of rat alveolar type I cells (Rishi et al, 1995).
Occasionally, focal expression of podoplanin can be found in
circumscribed areas of the basal layer of the human epidermis
(Schacht et al, 2005). As podoplanin is expressed on lymphatic but
not on blood vessel endothelium, it is widely used as a specific
marker for lymphatic endothelial cells and lymphangiogenesis in
many species (Breiteneder-Geleff et al, 1999).
The physiological function of podoplanin is still unknown.
Podoplanin-deficient mice die at birth owing to respiratory failure
exhibiting a phenotype of dilated, malfunctioning lymphatic
vessels and lymphoedema (Ramirez et al, 2003; Schacht et al,
2003). In addition, podoplanin can induce platelet aggregation in
vitro (Kaneko et al, 2006). In pathological situations studied thus
far, the mouse homologue of podoplanin (PA2.26, OTS-8) is
induced in mouse skin during tissue regeneration after wounding
and treatment with carcinogenic phorbol 12-myristate 13-acetate
(Gandarillas et al, 1997). OTS-8 is also induced by 12-O-
tetradecanoylphorbol-13-acetate in mouse osteoblastic cells and
is constitutively expressed in oncogenic Ras-transformed cells
(Nose et al, 1990). These findings suggest a role of podoplanin in
tissue development and repair as well as in carcinogenesis.
PODOPLANIN IS UPREGULATED IN THE OUTER
EDGE OF THE TUMOUR MASS
The expression of podoplanin is upregulated in a number of
different human cancers, including squamous cell carcinoma of
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and the skin, in dysgerminomas of the ovary and granulosa cell
tumours, in mesothelioma, and in many tumours of the central
nervous system (CNS) (Kato et al, 2005; Kimura and Kimura, 2005;
Martin-Villar et al, 2005; Schacht et al, 2005; Shibahara et al, 2006;
Wicki et al, 2006). The oncofetal M2A antigen expressed in
testicular germ cell tumours is identical to podoplanin (Dumoff
et al, 2005).
Until recently, tumours have been regarded as purely anaplastic
cell masses without a tissue-like organisation. There is growing
evidence, however, that the molecular expression pattern of cells in
the invading front of solid tumours is different from that of cells in
the tumour interior. For example, nuclear localisation of b-catenin
and upregulation of b1-integrin and the L1 cell adhesion molecule
were specifically observed in cells of the invasive tumour front
(Brabletz et al, 2001; Hegerfeldt et al, 2002; Gavert et al, 2005). We
have recently reported that in about 80% of human squamous cell
carcinomas (lung, larynx, cervix, skin and oesophagus) podopla-
nin is expressed – often in a one-cell layer – at the invasive edge of
the tumours (Wicki et al, 2006). In Figure 1, a cancer with single
cell invasion (panel A) is compared to a tumour with a collective-
cell invasion pattern (panel B). The restricted expression of
podoplanin at the front of human squamous cell carcinomas
prompted the question whether factors of the surrounding tissue
could influence podoplanin expression. Indeed, podoplanin
expression can be induced by epidermal growth factor, basic
fibroblast growth factor (FGF2) and tumour necrosis factor a in
MCF7 breast cancer cells, and by bradykinin in 3T3 fibroblasts
(Scholl et al, 1999; Wicki et al, 2006). Thus, podoplanin expression
may be modulated by the environment of the tumour. However,
the exact mechanisms of podoplanin regulation remain elusive.
PODOPLANIN BYPASSES EMT IN A MOUSE MODEL
OF CARCINOGENESIS
In many mouse models of carcinogenesis, EMT is a critical event
during the progression to tumour malignancy. One well-studied
model of multistep tumour progression is the Rip1Tag2 mouse
model of pancreatic b-cell carcinogenesis (Hanahan, 1985). These
mice express the simian virus large T antigen under the control
of the rat insulin promotor and reproducibly develop tumours of
the insulin-producing b cells of the islets of Langerhans. To
progress from a benign adenoma to malignant carcinoma, these
tumours need to lose E-cadherin expression and express N-
cadherin instead. This so-called cadherin switch, a molecular event
that is part of EMT, is a rate-limiting step in the transition from
adenoma to a carcinoma (Perl et al, 1998; Li and Herlyn, 2000).
Interestingly, transgenic expression of podoplanin in b-cell
tumours of Rip1Tag2 mice led to the formation of carcinomas in
the absence of a cadherin switch and EMT. In this model,
podoplanin shifted the invasion pattern from single cell invasion
involving EMT to the invasion of large cell sheets in the absence of
EMT. This notion is supported by the finding that forced
expression of podoplanin in MCF7 cells did not induce a
cadherin-switch or EMT, although the cells formed filopodia and
became more migratory and invasive (Wicki et al, 2006). However,
although most b-cell tumours did not undergo a cadherin switch in
podoplanin-expressing Rip1Tag2 tumour cells, a subset of the
tumours lost E-cadherin expression. These findings indicate that
(i) podoplanin does not suppress the cadherin switch or EMT, but
is able to mediate an independent pathway of tumour cell invasion,
and (ii) two different types of tumour invasion, involving or not
EMT, can coexist in one tumorigenesis pathway (Figure 2).
PODOPLANIN PROMOTES TUMOUR CELL
SPREADING, MIGRATION AND INVASION
Transfection studies with cultured normal and cancer cells were
employed to investigate the function of podoplanin in vitro.I n
both human keratinocytes and in MCF7 breast cancer cells, the
forced expression of podoplanin led to a dramatic change of
cellular morphology with a significant decrease of cellular stress
fibres and a concomitant formation of filopodia-like membrane
protrusions, even in the presence of E-cadherin expression (Scholl
et al, 1999; Wicki et al, 2006). Accordingly, adhesion and spreading
of cells on the extracellular matrix protein fibronectin was
enhanced by podoplanin expression. Such enhanced cell spreading
could be blocked by neutralising antibodies against b1-integrin.
The interaction between tumour cells and the ECM is a pre-
requisite for cell migration and invasion and, indeed, podoplanin
increased cell migration of MCF7 cells and HaCaT keratinocytes
in the presence of E-cadherin expression. In addition, invasion
of podoplanin-expressing cells through a layer of matrigel was
considerably enhanced in comparison to cells lacking podoplanin.
Invasion of podoplanin-expressing cells appeared to rely on the
activity of matrix metalloproteases (MMPs), as it could be
repressed by TIMP2, an inhibitor of MMP. These in vitro data
support the concept that podoplanin expression in human cancers
A
B
Figure 1 Human tumour samples stained for E-cadherin (brown) and
podoplanin (red) show single cell (A) and collective cell invasion (B). (A)
This adenocarcinoma of the colon invades into the surrounding tissue by
single cell invasion. Most of the cells of the tumour bulk (TU) express
E-cadherin. Single cells invading the tissue (arrows) have downregulated
E-cadherin. Podoplanin is not expressed in this cancer. (B) An oesophageal
carcinoma has formed an invasive cone that migrates into the surrounding
tissue. Podoplanin (red) is expressed in the outer edge of the invading
tumour. The tumour cells continue to express E-cadherin (brown) and
migrate collectively. Size bar¼50mm.
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of a cadherin switch and EMT. However, a recent report with
MDCK cells demonstrates that the expression of podoplanin leads
to increased single cell migration after loss of E-cadherin
expression (Martin-Villar et al, 2006). We therefore must postulate
that podoplanin is capable of inducing invasion in both settings,
collective and single cell migration. The molecular players and
mechanisms that govern the decision which of the two invasion
patterns is activated upon podoplanin expression are not known.
They may depend on cellular context and certainly warrant further
investigation.
PODOPLANIN MODULATES THE ACTIN
CYTOSKELETON
Cancer cell migration and invasion depend on an active
remodelling of the actin cytoskeleton. Yet, as podoplanin itself
has not been found to directly associate with actin in immuno-
precipitation assays, how then does it modulate the cytoskeleton?
Membrane proteins are linked via ERM proteins (ezrin, radixin
and moesin) to the actin cytoskeleton. One of the ERM proteins,
ezrin, has been shown to mediate filopodia formation and to
induce metastasis (Yu et al, 2004). Indeed, podoplanin physically
associates with ezrin (Scholl et al, 1999). In addition, over-
expression of podoplanin in MCF7 cells, MDCK cells and HaCaT
keratinocytes leads to a marked increase in phosphorylation of
ezrin and other ERM proteins without affecting ezrin or moesin
protein levels (Martin-Villar et al, 2006; Wicki et al, 2006). Thus,
ERM-protein phosphorylation may link podoplanin expression
to the observed rearrangement of the actin cytoskeleton. Apart
from ERM protein function, the activities of Rho-family GTPases,
in particular RhoA, are modulated by podoplanin. In MCF7 cells,
which express a high level of RhoA, podoplanin was found to
downregulate RhoA activity, whereas in MDCK cells, which exhibit
a low intrinsic activity of RhoA, its acitivity was enhanced by
podoplanin. The basis for this unexpected finding is not clear,
although it might reflect a different organisation of the cyto-
skeleton in different cell types (Martin-Villar et al, 2006). In both
cases, inhibition of RhoA modulation led to reduced cell motility,
strengthening the notion that the regulation of RhoA activity is
causally involved in the pro-migratory phenotype observed in
podoplanin-expressing cancer cells (Martin-Villar et al, 2006;
Wicki et al, 2006).
PODOPLANIN AS A TOOL FOR CANCER DIAGNOSIS
AND THERAPY
The expression of podoplanin in human cancers raises the
possibility to employ podoplanin expression as an immunohisto-
chemical marker for diagnosis and prognosis. Podoplanin expres-
sion is mainly detected in squamous cell cancers, CNS tumours
and germinal neoplasia. These cancers often express E-cadherin
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Figure 2 Two mechanisms are involved in the progression of an adenoma to a carcinoma: either the tumours undergo EMT, or they do not (non-EMT).
In EMT, the expression profile of adhesion molecules, components of the cytoskeleton and transcriptional regulators is changed. Although non-EMT
pathways of tumour invasion are less well studied, they also lead to alterations of the cytoskeleton and the adhesive apparatus. In addition, podoplanin and
possibly other mucin-like transmembrane proteins are involved.
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collective, cone-like manner. In contrast, expression of podoplanin
has not been found in the majority of adenocarcinomas, including
lung, colon and prostate cancers.
CNS tumours
Podoplanin is widely expressed in tumours of the CNS, including
ependymal tumours, choroid plexus papillomas, meningeomas,
pilocytic astrocytomas and glioblastomas. In malignant astrocytic
tumours, increased expression of podoplanin correlated with
higher histological tumour malignancy (Mishima et al, 2006).
However, because of its widespread expression in normal tissue,
podoplanin has been found of limited use for the diagnosis of CNS
tumours (Shibahara et al, 2006).
Cervix tumours
In a series of cervical cone biopsies and radical hysterectomies,
podoplanin was expressed in 71% of the samples. Focal expression
of podoplanin in the invading front but not in the tumour bulk was
present in 59% of the samples, whereas diffuse expression was
found in 12% of the cases investigated. Interestingly, focal
expression of podoplanin correlated with lymphatic invasion,
metastasis and a shorter recurrence-free survival, whereas diffuse
expression did not. Hence, podoplanin was proposed as a
prognostic marker for cervical cancer (Dumoff et al, 2005, 2006).
Germinal tumours
Podoplanin was found expressed in dysgerminomas of the ovary
and in granulosa cell tumours. It is uniformly expressed at high
levels in seminomas (98%), but also in embryonal carcinomas
(69%), teratomas (29%) and yolk sac tumours (25%). Thus, no
study has addressed the diagnostic or prognostic importance of
these findings (Schacht et al, 2005).
Squamous cell carcinoma of the skin and the lung
Of 28 skin cancer samples analysed, 79% expressed podoplanin.
Well-differentiated carcinomas did not express podoplanin, whereas
moderately differentiated carcinomas expressed podoplanin exclu-
sively in the invading front. Undifferentiated SCCs finally expressed
podoplanin beyond the basal cell layer with frequent cytoplasmic
staining (Schacht et al, 2005). Podoplanin is also upregulated in
squamous cell cancers of the lung (Wicki et al, 2006).
Mesothelioma
In a series of 30 mesotheliomas with epitheloid growth pattern,
93% expressed podoplanin. Podoplanin expression was also
observed on squamous cell carcinomas but not adenocarcinomas
of the lung (Ordonez, 2006a).
CONCLUSIONS
Different lines of evidence, sustained by genetic experiments and
life cell imaging, support the notion that tumour cells can invade
solitarily after loss of cell–cell adhesion, or as a group without
losing cell–cell contacts. Recently, we have shown that in human
squamous cell cancer, but also in an animal model of insulinoma,
podoplanin is involved in a pathway of collective cell migration
and invasion, which is independent from EMT (Wicki et al, 2006).
Interestingly, however, there is evidence that podoplanin can also
promote single cell invasion of MDCK cells and human oral
squamous cell carcinomas, thus contributing to EMT-mediated cell
motility (Martin-Villar et al, 2006). The molecular dissection of
collective and single cell invasion is a relatively new topic in cancer
research, whereas numerous efforts in the past and presence
attempt to distinguish these two pathways during embryonic
development. TGFb family members (such as Nodal), FGF, Wnt
signalling, cadherin cell adhesion molecules and eomesodermin
contribute to the collective migration of vertebrate embryonic
tissue. Yet, other TGFb family members (such as BMP), Snail
family members, FGFs and Wnt play a role in embryonic single cell
migration (reviewed by Locascio and Nieto, 2001). Thus, it seems
that several factors capable of inducing cell migration and invasion
can activate both collective and single cell migration and invasion.
Further research is required to unravel the molecular circum-
stances that modulate the effect of pro-migratory factors on their
target cells and determine the resulting invasion pattern.
Expression of podoplanin is also found upregulated in the
regenerating epidermis, and we speculate that podoplanin is part
of a pathway involving cell migration in the context of tissue repair
and that this pathway is also utilised by cancer cells during tumour
progression, giving them a selective advantage over less migratory
epithelial cells. Induction of podoplanin expression results in
multiple adjustments of intracellular signalling pathways, leading
to the modulation of Rho family GTPase activities, the phosphory-
lation of ERM proteins, rearrangement of the actin cytoskeleton
and, finally, enhanced cell migration and invasion.
However, some important questions concerning the function of
podoplanin in tumours remain open. The function of podoplanin
in human sarcomas, including angiosarcomas and Kaposi
sarcoma, where the expression of podoplanin is often more diffuse
and not restriced to the tumour front, needs to be elucidated
(Breiteneder-Geleff et al, 1999). The role of podoplanin expression
in carcinoma in situ also has to be addressed. As no expression of
podoplanin was found in many biopsies of adenocarcinomas (in
particular those of the colon and prostate), and these cancers often
exhibit the morphological characteristics of collective cell migra-
tion, we must assume that there are podoplanin-independent
pathways that also can elicit collective cell migration. Along these
lines, the function of other mucin-like cell surface proteins, such
as for example MUC1 (Figure 2), has to be clarified. Ultimately,
further elucidation of cellular pathways leading to different forms
of tumour cell invasion will help to devise new and more efficient
strategies against human cancer.
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